首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   118篇
  免费   5篇
耳鼻咽喉   1篇
基础医学   38篇
临床医学   3篇
内科学   9篇
神经病学   50篇
外科学   2篇
综合类   7篇
药学   12篇
中国医学   1篇
  2022年   1篇
  2021年   2篇
  2020年   5篇
  2019年   6篇
  2018年   9篇
  2017年   1篇
  2016年   4篇
  2014年   8篇
  2013年   6篇
  2012年   3篇
  2011年   6篇
  2010年   7篇
  2009年   3篇
  2008年   2篇
  2007年   2篇
  2006年   6篇
  2005年   1篇
  2003年   1篇
  2001年   1篇
  1999年   4篇
  1998年   2篇
  1997年   2篇
  1996年   3篇
  1995年   2篇
  1993年   2篇
  1990年   1篇
  1989年   1篇
  1988年   1篇
  1985年   1篇
  1984年   4篇
  1983年   5篇
  1982年   6篇
  1981年   7篇
  1980年   6篇
  1976年   2篇
排序方式: 共有123条查询结果,搜索用时 0 毫秒
121.
122.
The pure electrolectin, a beta-D-galactoside binding lectin from the electric organ of the electric eel Electrophorus electricus, was found to agglutinate selectively a subpopulation of mouse thymocytes. This cell population could be separated from non-agglutinated cells by 1 g sedimentation over fetal calf serum. The agglutinated cells could be identified as immature thymocytes on the basis of the density of theta-antigen they bear on their surfaces, their mitotic activity and the absence of response to the mitogenic action of phytohemagglutinin. The immature mouse thymocytes were found to bind the endogenous mouse thymic lectin (MTL) a protein that displays the same saccharide specificity as the eel electrolectin and with which it cross-reacts immunologically. MTL is secreted by mouse thymic reticulocytes in tissue culture and its specific activity is markedly increased after depleting the thymus of its thymocytes. This finding is an indication of the possible localization of MTL in the thymic epithelium. These results are discussed in the light of our recent findings that the eel electrolectin has prophylactic and therapeutic actions on the experimental auto-immune myasthenia gravis in rabbits.  相似文献   
123.

Background

We present a case of myositis and possible overlapping neuromuscular junction disorder following treatment with nivolumab for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Methods

We report a 75-year-old man with recurrent stage IVA, T1N2cM0 oral cavity HNSCC treated with weight-dosed nivolumab who presented three weeks later with severe fatigue, generalized weakness, and bilateral ptosis. Evaluation demonstrated elevated creatine kinase and myopathic motor units on electromyography, supporting a diagnosis of an underlying muscle disease. Elevated serum acetylcholine receptor binding antibodies raised the possibility of concurrent myasthenia gravis.

Results

He received corticosteroids and plasmapheresis without improvement in muscle weakness. His course was complicated by bacteremia, cardiac arrest, and concerns for recurrent malignancy. Following a two-month hospital stay, he was made comfort care and died.

Conclusions

With increasing usage of checkpoint inhibitors in HNSCC, clinicians must be aware of and vigilant for associated rare but serious adverse events.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号